Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
48
SRPT Quote, Financials, Valuation and Earnings
Last price:
$22.84
Seasonality move
:
10.18%
Day range:
$21.47 - $23.00
52-week range:
$10.42 - $131.31
Dividend yield:
0%
P/E ratio:
20.50x
P/S ratio:
0.93x
P/B ratio:
1.73x
Volume:
3.5M
Avg. volume:
5.3M
1-year change:
-82.67%
Market cap:
$2.3B
Revenue:
$1.9B
EPS (TTM):
-$2.89
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SRPT
Sarepta Therapeutics, Inc.
|
$337M | -$0.37 | -42.54% | -91.57% | $19.91 |
|
ARVN
Arvinas, Inc.
|
$27.6M | -$0.74 | -37.06% | -11.21% | $12.31 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$157.3M | -$0.16 | 9168.67% | -72.35% | $57.67 |
|
CDTX
Cidara Therapeutics, Inc.
|
-- | -$1.33 | -100% | -71.79% | $221.50 |
|
CYTK
Cytokinetics, Inc.
|
$6M | -$1.57 | -37.25% | -4.7% | $79.56 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.98% | 745.84% | $29.04 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SRPT
Sarepta Therapeutics, Inc.
|
$21.84 | $19.91 | $2.3B | 20.50x | $0.00 | 0% | 0.93x |
|
ARVN
Arvinas, Inc.
|
$12.55 | $12.31 | $806M | -- | $0.00 | 0% | 2.92x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$64.66 | $57.67 | $8.8B | -- | $0.00 | 0% | 10.41x |
|
CDTX
Cidara Therapeutics, Inc.
|
$220.50 | $221.50 | $6.9B | -- | $0.00 | 0% | 55.23x |
|
CYTK
Cytokinetics, Inc.
|
$64.66 | $79.56 | $7.9B | -- | $0.00 | 0% | 88.23x |
|
PFE
Pfizer Inc.
|
$25.57 | $29.04 | $145.4B | 14.90x | $0.43 | 6.73% | 2.32x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.307 | 61.92% | 1.42x |
|
ARVN
Arvinas, Inc.
|
1.66% | 2.758 | 1.57% | 5.58x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
61.15% | 4.654 | 15.55% | 4.74x |
|
CDTX
Cidara Therapeutics, Inc.
|
0.47% | 3.325 | 0.07% | 4.47x |
|
CYTK
Cytokinetics, Inc.
|
177.12% | 1.410 | 17.83% | 6.81x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
|
ARVN
Arvinas, Inc.
|
$40.6M | -$44M | -9.68% | -9.81% | -105.01% | -$59.2M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$250.1M | $44.1M | 2.57% | 7.7% | 17.2% | $13M |
|
CDTX
Cidara Therapeutics, Inc.
|
-$28K | -$43.6M | -68.01% | -68.74% | -3675.83% | -$40.6M |
|
CYTK
Cytokinetics, Inc.
|
-$743K | -$166.8M | -120.55% | -- | -8613.38% | -$116.9M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Sarepta Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SRPT or ARVN?
Arvinas, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of -83.77%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Arvinas, Inc.'s return on equity of -9.81%.
Company Gross Margin Earnings Per Share Invested Capital SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B ARVNArvinas, Inc.96.9% -$0.48 $573.9M -
What do Analysts Say About SRPT or ARVN?
Sarepta Therapeutics, Inc. has a consensus price target of $19.91, signalling downside risk potential of -8.84%. On the other hand Arvinas, Inc. has an analysts' consensus of $12.31 which suggests that it could fall by -1.89%. Given that Sarepta Therapeutics, Inc. has more downside risk than Arvinas, Inc., analysts believe Arvinas, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRPTSarepta Therapeutics, Inc.6 14 3 ARVNArvinas, Inc.7 9 1 -
Is SRPT or ARVN More Risky?
Sarepta Therapeutics, Inc. has a beta of 0.537, which suggesting that the stock is 46.348% less volatile than S&P 500. In comparison Arvinas, Inc. has a beta of 2.446, suggesting its more volatile than the S&P 500 by 144.578%.
-
Which is a Better Dividend Stock SRPT or ARVN?
Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Arvinas, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SRPT or ARVN?
Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are larger than Arvinas, Inc. quarterly revenues of $41.9M. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Arvinas, Inc.'s net income of -$35.1M. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Arvinas, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.93x versus 2.92x for Arvinas, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRPTSarepta Therapeutics, Inc.0.93x 20.50x $399.4M -$179.9M ARVNArvinas, Inc.2.92x -- $41.9M -$35.1M
-
Which has Higher Returns SRPT or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 6.29%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7%.
Company Gross Margin Earnings Per Share Invested Capital SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B ARWRArrowhead Pharmaceuticals, Inc.97.51% -$0.18 $1.2B -
What do Analysts Say About SRPT or ARWR?
Sarepta Therapeutics, Inc. has a consensus price target of $19.91, signalling downside risk potential of -8.84%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $57.67 which suggests that it could fall by -10.82%. Given that Arrowhead Pharmaceuticals, Inc. has more downside risk than Sarepta Therapeutics, Inc., analysts believe Sarepta Therapeutics, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRPTSarepta Therapeutics, Inc.6 14 3 ARWRArrowhead Pharmaceuticals, Inc.7 4 0 -
Is SRPT or ARWR More Risky?
Sarepta Therapeutics, Inc. has a beta of 0.537, which suggesting that the stock is 46.348% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, suggesting its more volatile than the S&P 500 by 27.862%.
-
Which is a Better Dividend Stock SRPT or ARWR?
Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SRPT or ARWR?
Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are larger than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $256.5M. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Arrowhead Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.93x versus 10.41x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRPTSarepta Therapeutics, Inc.0.93x 20.50x $399.4M -$179.9M ARWRArrowhead Pharmaceuticals, Inc.10.41x -- $256.5M $16.1M
-
Which has Higher Returns SRPT or CDTX?
Cidara Therapeutics, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of -30201.66%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.
Company Gross Margin Earnings Per Share Invested Capital SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M -
What do Analysts Say About SRPT or CDTX?
Sarepta Therapeutics, Inc. has a consensus price target of $19.91, signalling downside risk potential of -8.84%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.45%. Given that Cidara Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Cidara Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRPTSarepta Therapeutics, Inc.6 14 3 CDTXCidara Therapeutics, Inc.1 6 0 -
Is SRPT or CDTX More Risky?
Sarepta Therapeutics, Inc. has a beta of 0.537, which suggesting that the stock is 46.348% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.073%.
-
Which is a Better Dividend Stock SRPT or CDTX?
Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SRPT or CDTX?
Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are larger than Cidara Therapeutics, Inc. quarterly revenues of --. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.93x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRPTSarepta Therapeutics, Inc.0.93x 20.50x $399.4M -$179.9M CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M
-
Which has Higher Returns SRPT or CYTK?
Cytokinetics, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of -15814.98%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Cytokinetics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B CYTKCytokinetics, Inc.-38.38% -$2.55 $675.7M -
What do Analysts Say About SRPT or CYTK?
Sarepta Therapeutics, Inc. has a consensus price target of $19.91, signalling downside risk potential of -8.84%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $79.56 which suggests that it could grow by 23.04%. Given that Cytokinetics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Cytokinetics, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRPTSarepta Therapeutics, Inc.6 14 3 CYTKCytokinetics, Inc.9 4 0 -
Is SRPT or CYTK More Risky?
Sarepta Therapeutics, Inc. has a beta of 0.537, which suggesting that the stock is 46.348% less volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.584, suggesting its less volatile than the S&P 500 by 41.614%.
-
Which is a Better Dividend Stock SRPT or CYTK?
Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SRPT or CYTK?
Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are larger than Cytokinetics, Inc. quarterly revenues of $1.9M. Sarepta Therapeutics, Inc.'s net income of -$179.9M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.93x versus 88.23x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRPTSarepta Therapeutics, Inc.0.93x 20.50x $399.4M -$179.9M CYTKCytokinetics, Inc.88.23x -- $1.9M -$306.2M
-
Which has Higher Returns SRPT or PFE?
Pfizer Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 21.32%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About SRPT or PFE?
Sarepta Therapeutics, Inc. has a consensus price target of $19.91, signalling downside risk potential of -8.84%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Pfizer Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRPTSarepta Therapeutics, Inc.6 14 3 PFEPfizer Inc.7 15 1 -
Is SRPT or PFE More Risky?
Sarepta Therapeutics, Inc. has a beta of 0.537, which suggesting that the stock is 46.348% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock SRPT or PFE?
Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios SRPT or PFE?
Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.93x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRPTSarepta Therapeutics, Inc.0.93x 20.50x $399.4M -$179.9M PFEPfizer Inc.2.32x 14.90x $16.7B $3.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 5
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
